{"url":"https://newsforagent.com/news/2026-10-20/icecure-medical-choice-study-enrollment","markdown_url":"https://newsforagent.com/news/2026-10-20/icecure-medical-choice-study-enrollment.md","title":"IceCure Medical Enrolls First 2 Patients in ProSense Breast Cancer Study","headline":"IceCure Medical Enrolls First Two Patients in FDA-Cleared ChoICE Breast Cancer Cryoablation Study","description":"IceCure Medical enrolled the first two patients in its FDA-cleared ChoICE study of ProSense cryoablation for low-risk breast cancer.","section":"Research & Clinical Trials","published_at":"2026-10-20T12:24:43+00:00","modified_at":"2026-10-20T12:24:43+00:00","author":"News Desk","key_takeaways":["IceCure Medical enrolled the first two patients in its FDA-cleared ChoICE study of ProSense cryoablation for low-risk breast cancer.","The ChoICE study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites.","The first patient was enrolled at West Cancer Center in Germantown, Tennessee, and the second at Adventist Health Glendale in Glendale, California."],"companies":[{"name":"IceCure Medical","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00025yi/icecure-medical","website":"http://icecure-medical.com"},{"name":"Adventist Health","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000afnk/adventist-health","website":"https://www.adventisthealth.org"},{"name":"West Cancer Center","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000cd1z/west-cancer-center","website":"http://www.westcancercenter.org"}],"source":{"publisher":"Stock Titan","title":"IceCure Enrolls First 2 Patients in Breast Cancer Study","url":"https://www.stocktitan.net/news/ICCM/ice-cure-enrolls-first-patients-in-its-fda-approved-study-for-pro-svaosppam34e.html"},"other_sources":[],"tags":["Research & Clinical Trials","IceCure Medical","Adventist Health","West Cancer Center"],"body_markdown":"[IceCure Medical](https://akta.pro/company-profiles/00025yi/icecure-medical) enrolled the first two patients in its FDA-cleared ChoICE study of ProSense cryoablation for the local treatment of low-risk breast cancer, the company said on October 20, 2026. Stock Titan [published](https://www.stocktitan.net/news/ICCM/ice-cure-enrolls-first-patients-in-its-fda-approved-study-for-pro-svaosppam34e.html) the announcement.\n\n## IceCure's First Enrollments at Two U.S. Sites\n\nThe first patient was enrolled at [West Cancer Center](https://akta.pro/company-profiles/000cd1z/west-cancer-center) & Research Institute in Germantown, Tennessee, by Dr. Richard E. Fine, MD, FACS, director of the Margaret West Comprehensive Breast Center and lead author of the ICE3 Study on cryoablation of small, low-risk breast cancer. The second patient was enrolled at [Adventist Health](https://akta.pro/company-profiles/000afnk/adventist-health) Glendale in Glendale, California, a site led by breast surgeon Dr. Dennis Holmes, MD, FACS.\n\nBoth sites announced their eligibility to enroll patients in August 2026 after signing a site agreement and receiving IRB approval. Earlier in October 2026, IceCure announced the addition of Legacy Health's Legacy Medical Group - Surgical Oncology at Good Samaritan Medical Center in Portland, Oregon, expanding the ChoICE Study's U.S. clinical network.\n\n\"Enrolling the first patients marks continued progress in the execution of our post-market strategy for ProSense,\" said Eyal Shamir, chief executive officer of IceCure Medical. \"As we continue to expand the ChoICE Study's clinical network, we aim to generate additional real-world evidence while supporting broader clinical adoption and access to minimally invasive cryoablation for eligible patients.\"\n\nThe ChoICE Study is designed to enroll approximately 400 patients across up to 30 U.S. clinical sites and generate real-world data on ProSense in its FDA-cleared indication. Participating sites are expected to serve as both study centers and active commercial sites, enabling them to offer ProSense cryoablation to eligible patients who are not participating in the ChoICE Study.\n\n## IceCure's ProSense Business at a Glance\n\nAccording to akta.pro [company records](https://akta.pro/company-data), IceCure Medical reported full-year 2025 revenue of $3.4 million, up 3% from $3.3 million in 2024, and a net loss of $15.1 million, narrowed from $15.3 million in 2024. The same records show a 70% increase in the active U.S. commercial install base for ProSense breast cancer cryoablation systems following FDA marketing authorization in October 2025.\n\n## IceCure's Earlier 2026 Milestones\n\nIceCure Medical received Class III medical device approval from China's NMPA for its ProSense cryoablation system and cryoprobes in September 2026, Stock Titan reported. In August 2026, the company entered an exclusive distribution agreement with Scovas Medical to distribute ProSense cryoablation systems in the Netherlands, according to Stock Titan.\n\n## What Comes Next for the ChoICE Study\n\nIceCure Medical said participating sites are expected to offer ProSense commercially to eligible patients who are not enrolled in the ChoICE Study.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}